| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
| Targets |
cis-5-Dodecenoic acid targets the cyclooxygenase enzymes COX-I and COX-II. These enzymes are key in the prostaglandin synthesis pathway, which is responsible for producing prostanoids involved in inflammation and pain. By inhibiting COX activity, the compound reduces the production of prostaglandins. It is an endogenous metabolite.
|
|---|---|
| ln Vitro |
cis-5-Dodecenoic acid exhibits in vitro inhibitory activity against both COX-I and COX-II. Its primary in vitro activity is the reduction of prostaglandin synthesis through direct inhibition of COX enzyme activity. It serves as an ideal negative control in experiments because it lacks antioxidant activity. Specific IC50 values are not detailed in the general product information.
|
| ln Vivo |
In vivo activity data for cis-5-Dodecenoic acid are not extensively described, but its role as an endogenous metabolite suggests it participates in fatty acid metabolism pathways in the body. Its involvement in the fatty acid β-oxidative metabolic pathway indicates it may be processed and utilized for energy. However, as a research tool, it is more commonly used in in vitro settings to study COX inhibition.
|
| Enzyme Assay |
Non-cellular assays for cis-5-Dodecenoic acid typically involve measuring its inhibition of COX enzyme activity in a cell-free system. Purified COX-I or COX-II enzymes are incubated with arachidonic acid (the substrate) and varying concentrations of the compound. The production of prostaglandins (e.g., PGE2) is then measured using an ELISA or a similar detection method. The compound's inhibitory potency (IC50) is calculated from the dose-response curve.
|
| Cell Assay |
In vitro cellular assays for cis-5-Dodecenoic acid often involve culturing cells that produce prostaglandins, such as macrophages or other inflammatory cells. The cells are stimulated (e.g., with LPS) to induce COX expression and prostaglandin synthesis, then treated with the compound. The amount of prostaglandins (like PGE2) released into the culture medium is quantified. The compound's anti-inflammatory effect is determined by its ability to reduce prostaglandin production.
|
| Animal Protocol |
In vivo animal studies for cis-5-Dodecenoic acid are not standardly described. As an endogenous metabolite and a tool for studying fatty acid metabolism, it could be administered to animals to study its effects on metabolic pathways. However, its primary use is as an in vitro research tool and a negative control.
|
| ADME/Pharmacokinetics |
Pharmacokinetic (PK) properties of cis-5-Dodecenoic acid are not extensively detailed. As a fatty acid, it is expected to be absorbed and metabolized. It is involved in the fatty acid β-oxidation pathway, but its metabolic rate is significantly lower than that of saturated fatty acids. This suggests a longer residence time or a different metabolic fate compared to other fatty acids.
|
| Toxicity/Toxicokinetics |
Specific toxicological data for cis-5-Dodecenoic acid are not extensively available in standard product documentation. As an endogenous fatty acid, it is generally considered to be of low toxicity. However, as a research chemical, it should be handled with standard laboratory precautions. It is not intended for human use.
|
| References | |
| Additional Infomation |
cis-5-dodecenoic acid is the cis stereoisomer of 5-dodecenoic acid. It has been reported that agarwood (Aquilaria sinensis) contains cis-5-dodecenoic acid, and relevant data are available for reference.
cis-5-Dodecenoic acid is a research-grade biochemical intended for laboratory use only and is not approved for clinical use. Its CAS number is 2430-94-6, and its molecular formula is C₁₂H₂₂O₂. Its primary applications are in the research of anti-inflammation, fatty acid metabolism mechanisms, and related physiological and pathological processes. Due to its lack of antioxidant activity, it is also used as an ideal negative control in studies of fatty acid biology. |
| Molecular Formula |
C12H22O2
|
|---|---|
| Molecular Weight |
198.30188
|
| Exact Mass |
198.162
|
| CAS # |
2430-94-6
|
| PubChem CID |
5312378
|
| Appearance |
Colorless to light yellow liquid
|
| Density |
0.922g/cm3
|
| Boiling Point |
310.6ºC at 760mmHg
|
| Flash Point |
207.7ºC
|
| Vapour Pressure |
0mmHg at 25°C
|
| Index of Refraction |
n20/D 1.454(lit.)
|
| LogP |
3.767
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
9
|
| Heavy Atom Count |
14
|
| Complexity |
162
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
C(O)(=O)CCC/C=C/CCCCCC
|
| InChi Key |
IJBFSOLHRKELLR-FPLPWBNLSA-N
|
| InChi Code |
InChI=1S/C12H22O2/c1-2-3-4-5-6-7-8-9-10-11-12(13)14/h7-8H,2-6,9-11H2,1H3,(H,13,14)/b8-7-
|
| Chemical Name |
(Z)-dodec-5-enoic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~504.29 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (12.61 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (12.61 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (12.61 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.0429 mL | 25.2143 mL | 50.4286 mL | |
| 5 mM | 1.0086 mL | 5.0429 mL | 10.0857 mL | |
| 10 mM | 0.5043 mL | 2.5214 mL | 5.0429 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
